Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19

NCT04941105 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Sars-CoV-2 Infection

Interventions

DRUG: Evolocumab
DRUG: Saline solution

Sponsor

Collegium Medicum w Bydgoszczy